Skip to main content
Clinical Trials/EUCTR2020-003183-68-IT
EUCTR2020-003183-68-IT
Active, not recruiting
Phase 1

The Role of Imaging Guided Surgery to Improve the Detection of LymphNode metastases in Prostate Cancer Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection - PSMA-RGS

OSPEDALE SAN RAFFAELE0 sites100 target enrollmentJune 15, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Patients with prostate cancer (PCa) who are candidate to undergo surgical treatment with robot-assisted radical prostatectomy with a risk of lymph nodal invasion > 5% according to preoperative data
Sponsor
OSPEDALE SAN RAFFAELE
Enrollment
100
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 15, 2021
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Sponsor
OSPEDALE SAN RAFFAELE

Eligibility Criteria

Inclusion Criteria

  • \-Male patients
  • \-Age between 18 and 80 years
  • \-Biopsy proven PCa with a LNI risk \>5% according to the Briganti nomogram
  • \-Planned to receive a RARP with an ePLND
  • \-Able to understand and willing to sign a written informed consent document
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 50
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • \-Receipt of neoadjuvant therapies
  • \-Inability to complete the imaging examinations according to the prospective protocol
  • \-Evidence of metastatic disease at conventional imaging before surgery
  • \-Evidence of clinical lymphadenopathies at conventional imaging before surgery
  • \-Life expectancy of less than 12 months
  • \-Previous chemotherapy
  • \-Previous brachytherapy or external beam radiotherapy
  • \-Unstable cardiovascular disease
  • \-Congestive Heart Failure (CHF)
  • \-Clinically significant hepatobiliary or renal disease

Outcomes

Primary Outcomes

Not specified

Similar Trials